Jazz Pharma Plc (JAZZ) Stock Price, Quote & News

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 634 7800

Website: www.jazzpharma.com

Address:

Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland

BillionerOfKing Dec. 4 at 10:33 AM

$JAZZ Current Stock Price: $166.99 Contracts to trade: $165 JAZZ Dec 19 2025 Call Entry: $8.87 Exit: $16.95 ROI: 91% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Night_Owl_Biotech Dec. 1 at 10:15 PM

Commercial-stage oncology focused biopharma valuation related data points as of 12/1/25 (market caps $1B+). $NVCR traded at the lowest multiple in this peer group as of last Friday but leadership changes announced this morning pushed its multiples even lower. Exercise caution as only 1 analyst provides FY29 estimates (4 analysts provide FY28). $SNDX was off 3.5% today after this morning announcing a presentation at an Evercore investor event this Thursday 12/4/25. Every SNDX investor (and their parents) anticipate an $INCY acquisition. Does this douse the M&A enthusiasm? SNDX otherwise trades at the 2nd lowest multiple of analyst revenue projections in the peer group. $LEGN & $JAZZ are the next lowest in this peer group as of 12/1/25 For entertainment only. This is not investment advice.

2 · Reply

smartkarma Nov. 29 at 6:04 PM

$JAZZ | Jazz Pharmaceuticals Inside Story: How CNS & Oncology Deals Are Building a New Revenue Machine! "Jazz Pharmaceuticals reported a strong performance in the third quarter of 2025, achieving a record revenue surpassing $1.1 billion. The growth..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/jazz-pharmaceuticals-inside-story-how-cns-oncology-deals-are-building-a-new-revenue-machine

0 · Reply

Floyd_Dalton Nov. 28 at 3:11 PM

$SLS $CPXX $JAZZ $CADL CPXX was bought for around $30.00/ share only weeks after p3 aml. It ran 1600% in a few months. I bought it around $4.00

1 · Reply

Floyd_Dalton Nov. 28 at 3:09 PM

$SLS $CPXX $JAZZ $CADL is next on that bp list

0 · Reply

Night_Owl_Biotech Nov. 27 at 3:37 PM

The XBI is up 14% the last 3 weeks, trading higher 12 of the last 16 days. It appears commercial-stage oncology is finally starting to catch up as more than half beat the XBI over this period. Attached is a list of all such bios since the XBI began its latest surge after 11/4/25's close $RIGL has been the best stock in this peer group over this time $NUVB was #2 but did report new data We thought $IMCR was doomed to trade at 3X KimmTrak sales forever (between $30 & $35) until the Phase 3 reads in late 2026 $JAZZ is more impressive because its capital structure includes considerable debt (hence share price gains are more than linear to valuation) Even the mega bio $EXEL beat the index Eventually, LEGN has to turn This is not investment advice.

0 · Reply

SweepCastApp Nov. 26 at 6:03 PM

$JAZZ: Unusual Options Activity Alerted CALL flow observed 165x contracts at Strike price of $185 Exp on 12/19/2025 with Premium of $33K and showing BEARISH Sentiment market signals turning up

0 · Reply

ZacksResearch Nov. 26 at 3:54 PM

Stealth cannabis play hiding in plain sight? $JAZZ might be it. Epidiolex’s rising sales plus a broad drug portfolio are helping the company tighten its grip on the evolving medical cannabis space — a combo most investors are sleeping on. Full breakdown here 👉 https://www.zacks.com/stock/news/2795846/why-jazz-pharmaceuticals-may-be-a-stealth-cannabis-winner?cid=sm-stocktwits-2-2795846-teaser-22577&ADID=SYND_STOCKTWITS_TWEET_2_2795846_TEASER_22577

0 · Reply

ZacksResearch Nov. 26 at 2:54 PM

$JAZZ is quietly carving out a cannabis niche — here’s why it matters! 🌿 Epidiolex, a CBD-derived oral solution, now represents 25% of Jazz’s revenue, with sales growing 11% year over year in the first nine months of 2025. As one of the few FDA-approved cannabis-based products, it’s on track for blockbuster status, positioning Jazz for long-term gains in the booming medical cannabis market. Find out what else drives JAZZ’s growth 👇 https://www.zacks.com/stock/news/2795846/why-jazz-pharmaceuticals-may-be-a-stealth-cannabis-winner?cid=sm-stocktwits-2-2795846-body-22572&ADID=SYND_STOCKTWITS_TWEET_2_2795846_BODY_22572

0 · Reply

JarvisFlow Nov. 24 at 2:57 PM

UBS has updated their rating for Jazz Pharmaceuticals ( $JAZZ ) to Neutral with a price target of 188.

0 · Reply

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting

Dec 5, 2025, 7:12 AM EST - 1 day ago

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

Dec 2, 2025, 4:05 PM EST - 4 days ago

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium

Dec 2, 2025, 1:13 PM EST - 4 days ago

Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 18, 2025, 4:15 PM EST - 18 days ago

Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 17, 2025, 4:53 PM EST - 19 days ago

Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence

Nov 17, 2025, 2:43 PM EST - 19 days ago

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

ZYME

Nov 17, 2025, 12:09 PM EST - 19 days ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

ZYME

Nov 17, 2025, 8:10 AM EST - 19 days ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

ZYME

Nov 17, 2025, 6:00 AM EST - 19 days ago

Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom

Nov 11, 2025, 7:45 AM EST - 25 days ago

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

Nov 5, 2025, 8:41 PM EST - 4 weeks ago

Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 4 weeks ago

Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Nov 2, 2025, 2:24 PM EST - 4 weeks ago

Aristotle Global Equity Advisory Q3 2025 Contributors And Detractors

ALC CCJ FCFS LEN MCHP MLM

Oct 28, 2025, 4:05 PM EDT - 5 weeks ago

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Oct 22, 2025, 4:15 PM EDT - 6 weeks ago

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

Oct 21, 2025, 7:00 AM EDT - 6 weeks ago

Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer

Oct 17, 2025, 1:47 PM EDT - 7 weeks ago

3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street

AEHR TZOO

Oct 2, 2025, 6:37 PM EDT - 2 months ago

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Oct 2, 2025, 3:37 PM EDT - 2 months ago

US FDA approves Jazz Pharma's therapy for lung cancer

Sep 24, 2025, 10:45 AM EDT - 2 months ago

Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating

Sep 22, 2025, 7:45 AM EDT - 2 months ago

Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

Sep 9, 2025, 7:45 AM EDT - 3 months ago

Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

Sep 3, 2025, 1:21 PM EDT - 3 months ago

Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 21, 2025, 4:15 PM EDT - 3 months ago

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 4:15 PM EDT - 3 months ago

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

Aug 20, 2025, 7:30 AM EDT - 3 months ago

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Aug 6, 2025, 3:07 PM EDT - 4 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Aug 6, 2025, 3:00 PM EDT - 4 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 10:00 AM EDT - 4 months ago

Jazz (JAZZ) Q2 Revenue Rises 2%

Aug 6, 2025, 5:33 AM EDT - 4 months ago

Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 4 months ago

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jul 22, 2025, 4:15 PM EDT - 4 months ago

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Jul 10, 2025, 7:30 AM EDT - 5 months ago

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Jul 7, 2025, 10:05 AM EDT - 5 months ago

Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 9:30 AM EDT - 5 months ago

Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor

Jul 1, 2025, 8:31 AM EDT - 5 months ago

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jun 10, 2025, 7:05 AM EDT - 6 months ago

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jun 9, 2025, 6:00 PM EDT - 6 months ago

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jun 2, 2025, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jun 2, 2025, 12:35 PM EDT - 6 months ago

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

May 29, 2025, 7:30 AM EDT - 6 months ago

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 21, 2025, 4:30 PM EDT - 7 months ago

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025, 4:58 AM EDT - 7 months ago

Jazz Pharmaceuticals: One Step Forward, One Back

May 6, 2025, 11:06 PM EDT - 7 months ago

Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 7 months ago

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Apr 30, 2025, 4:15 PM EDT - 7 months ago

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Apr 25, 2025, 11:27 AM EDT - 8 months ago

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Apr 23, 2025, 4:15 PM EDT - 8 months ago

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Apr 22, 2025, 4:15 PM EDT - 8 months ago

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

BillionerOfKing Dec. 4 at 10:33 AM

0 · Reply

Night_Owl_Biotech Dec. 1 at 10:15 PM

2 · Reply

smartkarma Nov. 29 at 6:04 PM

0 · Reply

Floyd_Dalton Nov. 28 at 3:11 PM

$SLS $CPXX $JAZZ $CADL CPXX was bought for around $30.00/ share only weeks after p3 aml. It ran 1600% in a few months. I bought it around $4.00

1 · Reply

Floyd_Dalton Nov. 28 at 3:09 PM

$SLS $CPXX $JAZZ $CADL is next on that bp list

0 · Reply

Night_Owl_Biotech Nov. 27 at 3:37 PM

0 · Reply

SweepCastApp Nov. 26 at 6:03 PM

$JAZZ: Unusual Options Activity Alerted CALL flow observed 165x contracts at Strike price of $185 Exp on 12/19/2025 with Premium of $33K and showing BEARISH Sentiment market signals turning up

0 · Reply

ZacksResearch Nov. 26 at 3:54 PM

0 · Reply

ZacksResearch Nov. 26 at 2:54 PM

0 · Reply

JarvisFlow Nov. 24 at 2:57 PM

UBS has updated their rating for Jazz Pharmaceuticals ( $JAZZ ) to Neutral with a price target of 188.

0 · Reply

briefingcom Nov. 24 at 2:06 PM

$JAZZ: Jazz Pharma downgraded to Neutral from Buy at UBS, $188 View Today's Stock Downgrades: https://www.briefing.com/calendars/updown?Filter=downgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link

0 · Reply

Doozio Nov. 23 at 5:02 PM

$LFCR chop chop huckleberries rotation and all that $JAZZ 🐒🍌🧠⏰♾️

0 · Reply

BigWaveTrading Nov. 22 at 10:13 AM

$XLV Continues To Lead With The Overall Market Under Red-Flag Conditions; Two New Swing Setups In this video I review the overall market, the leadership in Medical/Biotech names, and two new long positions I am entering on Monday. $JAZZ $ONC $XBI https://www.youtube.com/watch?v=8WXLvnua8-E

0 · Reply

Tiffanytrump Nov. 19 at 12:56 PM

$AVDL bidding war getting warmed up! Wake up $JAZZ $PFE $TMC

0 · Reply

piesky Nov. 18 at 8:48 PM

$JAZZ where did that cousin Bruce spammer loser go?

0 · Reply

JarvisFlow Nov. 18 at 7:21 PM

Wells Fargo has adjusted their stance on Jazz Pharmaceuticals ( $JAZZ ), setting the rating to Overweight with a target price of 170 → 235.

1 · Reply

Stocktwits Nov. 18 at 6:29 PM

$JAZZ Anyone looking at biotech?

0 · Reply

ZacksResearch Nov. 18 at 5:20 PM

$JAZZ ripping to a 52-week high — and the catalyst looks legit. HERIZON-GEA-01 showed Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA, and that kind of clinical momentum can keep buyers leaning in. Full breakdown of the move 👉 https://www.zacks.com/stock/news/2792687/jazz-hits-52-week-high-on-encouraging-gastric-cancer-study-data?cid=sm-stocktwits-2-2792687-teaser-21498&ADID=SYND_STOCKTWITS_TWEET_2_2792687_TEASER_21498

0 · Reply

ZacksResearch Nov. 18 at 4:20 PM

$JAZZ hit a 52-week high! 🚀 What's driving the surge? Jazz Pharmaceuticals announced positive top-line results from the HERIZON-GEA-01 study, showing significant improvements in PFS and statistically significant OS for the three-drug regimen of its drug Ziihera in treating HER2+ GEA. This could set the stage for it to become the new standard of care. See why this could be a game-changer for Jazz 👉 https://www.zacks.com/stock/news/2792687/jazz-hits-52-week-high-on-encouraging-gastric-cancer-study-data?cid=sm-stocktwits-2-2792687-body-21486&ADID=SYND_STOCKTWITS_TWEET_2_2792687_BODY_21486

0 · Reply

JarvisFlow Nov. 18 at 3:26 PM

Baird updates rating for Jazz Pharmaceuticals ( $JAZZ ) to Outperform, target set at 160 → 209.

0 · Reply

CubensisMoya Nov. 18 at 3:03 PM

$JAZZ low volume float, shares short are 🚀 someone is going to be holding on to some bags for along time

0 · Reply

Market Cap	10.31B
Revenue (ttm)	4.07B
Net Income (ttm)	560.12M
EPS (ttm)	N/A
PE Ratio	39.55
Forward PE	41.28
Profit Margin	13.77%
Debt to Equity Ratio	1.35

Volume	910,200
Avg Vol	1,055,430
Day's Range	N/A - N/A
Shares Out	60.77M
Stochastic %K	29%
Beta	0.30
Analysts	Strong Sell
Price Target	$209.33